Cargando…
4‐protein signature predicting tamoxifen treatment outcome in recurrent breast cancer
Estrogen receptor (ER) positive tumors represent the majority of breast malignancies, and are effectively treated with hormonal therapies, such as tamoxifen. However, in the recurrent disease resistance to tamoxifen therapy is common and a major cause of death. In recent years, in‐depth proteome ana...
Autores principales: | De Marchi, Tommaso, Liu, Ning Qing, Stingl, Cristoph, Timmermans, Mieke A., Smid, Marcel, Look, Maxime P., Tjoa, Mila, Braakman, Rene B.H., Opdam, Mark, Linn, Sabine C., Sweep, Fred C.G.J., Span, Paul N., Kliffen, Mike, Luider, Theo M., Foekens, John A., Martens, John W.M., Umar, Arzu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528925/ https://www.ncbi.nlm.nih.gov/pubmed/26285647 http://dx.doi.org/10.1016/j.molonc.2015.07.004 |
Ejemplares similares
-
Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2015) -
Global proteomic characterization of microdissected estrogen receptor positive breast tumors
por: De Marchi, Tommaso, et al.
Publicado: (2015) -
Comparative Proteome Analysis Revealing an 11-Protein Signature for Aggressive Triple-Negative Breast Cancer
por: Liu, Ning Qing, et al.
Publicado: (2014) -
Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2017) -
Proteomic characterization of microdissected breast tissue environment provides a protein‐level overview of malignant transformation
por: Braakman, René B. H., et al.
Publicado: (2017)